Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas' preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01 billion in development, regulatory, and commercial milestones, as well as tiered royalties –

– Novartis to be responsible for worldwide clinical development and commercialization of ARV-766 –

– Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer –

NEW HAVEN, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas' second generation PROTAC ® androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas' preclinical AR-V7 program to Novartis.

"We are thrilled to partner with an organization that shares our dedication to delivering transformative medicines to patients with significant unmet need," said John Houston, Ph.D., Chairperson, President and Chief Executive Officer of Arvinas. "We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer. This strategic transaction also further validates our innovative PROTAC protein degrader platform and its potential to deliver new treatments."

Under the terms of the transaction agreements, Novartis will be responsible for worldwide clinical development and commercialization of ARV-766 and will have all research, development, manufacturing, and commercialization rights with respect to the preclinical AR-V7 program. Arvinas will receive an upfront payment in the aggregate amount of $150.0 million. Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.

Closing of the transaction is subject to the parties' receipt of any necessary consents or approvals, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.

About ARV-766
ARV-766 is an investigational orally bioavailable PROTAC ® protein degrader designed to selectively target and degrade the androgen receptor (AR). Preclinically, ARV-766 has demonstrated activity in models of wild type androgen receptor tumors in addition to tumors with AR mutations or amplification, both common potential mechanisms of resistance to currently available AR-targeted therapies.

About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC ® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC ® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of patients with metastatic castration-resistant prostate cancer; and ARV-102 for the treatment of patients with neurodegenerative disorders. For more information, visit .

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential for ARV-766 to be a first- and best-in-class treatment for patients with prostate cancer, the potential of Arvinas' PROTAC protein degrader platform and its potential to deliver new treatments, the closing of the transaction with Novartis, the receipt of upfront, milestone, and royalty payments in connection with the transaction and the future development, potential marketing approval and commercialization of ARV-766. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: the satisfaction or waiver of the closing conditions set forth in the license agreement with Novartis, each party's performance of its obligations under the license agreement, whether Novartis will be able to successfully conduct and complete clinical development, obtain marketing approval for and commercialize ARV-766, and other important factors discussed in the "Risk Factors" section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release.

Arvinas Contacts

Investor Contact:
Jeff Boyle, Arvinas Investor Relations
+1 (347) 247-5089

Media Contact:
Kathleen Murphy, Arvinas Communications
+1 (760) 622-3771

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Element 25 Limited

Element 25 Announces Share Purchase Plan

Element 25 Limited (E25 or Company) (ASX: E25; OTCQX: ELMTF) will offer eligible shareholders the opportunity to participate in a non-underwritten share purchase plan (SPP), targeting to raise $5 million (before costs).

Keep reading...Show less
Element 25 Limited

E25 Secures Key Permit for USA HPMSM Site

Element 25 Limited (E25 or Company) (ASX: E25; OTCQX: ELMTF) is pleased to advise it has been issued with a Title V Air Permit for the construction of an Electric Vehicle (EV) battery grade high-purity manganese sulphate monohydrate (HPMSM) refinery in Louisiana, USA (Project) via subsidiary Element 25 (Louisiana) LLC (E25LA).

Keep reading...Show less


Silver One Resources Inc. (TSXV: SVE) (OTCQX: SLVRF) (FSE: BRK1) ("Silver One" or the "Company") is pleased to announce the discovery of additional large silver vein fragments along the major east-west 417 vein structure, immediately to the west of the large angular and unabraded 417 pound (189 kg) silver vein fragment that was estimated to contain over 70% silver (see February 5, 2020 January 11, 2021 company's news releases and Figure 1).  The distribution of these newly discovered vein fragments, one weighing up to 6+ pounds (2.7 kg), extends the area of potential mineralization 600+ metres to the west of the 417 pound silver vein fragment (see Figure 2 below), significantly expanding the area of potential high-grade silver prospectivity.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with
ACTengine® IMA203 TCR-T Targeting PRAME

  • Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor shrinkage achieved in 87% of patients; median duration of response of 13.5 months including 11/16 ongoing confirmed responses; IMA203 continues to maintain a favorable safety profile
  • Registration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 in 2L+ melanoma planned to commence in 2024 following further discussions with FDA
  • Next data update on IMA203 and IMA203CD8 (GEN2) planned for 2H 2024
  • First clinical data updates for Immatics' next-generation, half-life extended TCR Bispecifics, TCER® IMA401 (MAGEA4/8) and TCER® IMA402 (PRAME), from ongoing Phase 1 dose escalation trials planned for 2H 2024; updates to include details on safety, pharmacokinetics and initial anti-tumor activity
  • $201.5 million public offering completed on January 22, 2024
  • Cash and cash equivalents, as well as other financial assets, amount to $609.7 million 1 (€564.0 million) as of March 31, 2024 funding company operations into 2027

Houston, Texas and Tuebingen, Germany, May 14, 2024 Immatics N.V. (NASDAQ: IMTX, "Immatics"), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today provided a business update and reported financial results for the quarter ended March 31, 2024.

"Our lead cell therapy candidate, IMA203, continues to show deep and durable responses in a significantly expanded data set since our last data readout in November 2023. This update emphasizes the meaningful impact our novel immunotherapy may have on the lives of metastatic cutaneous, uveal and mucosal melanoma patients and the medical needs that IMA203 has a real opportunity to address. We continue to plan to move IMA203 into a registration-enabling clinical trial within this year while also continuing to ramp up our commercial manufacturing buildout," said Harpreet Singh, Ph.D., CEO and Co-Founder of Immatics. "In addition to IMA203's progress, we also look forward to presenting the first clinical data on the two lead candidates from our bispecifics pipeline in the second half of the year."

First Quarter 2024 and Subsequent Company Progress

ACTengine® Cell Therapy Program

ACTengine® IMA203 monotherapy
Today, Immatics is providing a data update on IMA203 monotherapy targeting PRAME from the ongoing Phase 1 trial at the recommended Phase 2 dose (RP2D, 1 to 10 billion total TCR-T cells) in 30 heavily pretreated metastatic melanoma patients evaluable for efficacy. The treated patient population is composed of patients with a median of 3 lines of prior systemic treatments, consisting of cutaneous melanoma patients (N=17), uveal melanoma patients (N=10), mucosal melanoma patients (N=2) and a patient with melanoma of unknown primary (N=1). The current data represent an update to the previously communicated interim data readout in the IMA203 melanoma efficacy population of November 8, 2023 .

As of the data cut-off on April 25, 2024, treatment with IMA203 monotherapy in the efficacy population has demonstrated:

  • Confirmed objective response rate (cORR) of 55% (16/29)
  • Disease control rate of 90% (27/30)
  • Tumor shrinkage in 87% (26/30) of patients
  • Median duration of response (mDOR) was 13.5 months (min 1.2+, max 21.5+ months) including 11 of 16 confirmed objective responses ongoing at data cut-off and longest duration of response ongoing at >21 months after infusion
  • Confirmed response rates are similar across all melanoma subtypes (56% (9/16) in cutaneous melanoma; 54% (7/13) in other melanoma subtypes)

To date, IMA203 has maintained a favorable safety profile with no treatment-related grade 5 events in the safety population (N=65 patients across all dose levels and all tumor types).

Best overall response for IMA203 at RP2D in melanoma

More information and details on the IMA203 clinical data update in melanoma are available in the Immatics corporate presentation:

The next data update with translational and clinical data for IMA203 is planned for 2H 2024 at a medical conference.

Immatics' late-stage clinical cell therapy development is supported by its differentiated manufacturing related to timeline, capabilities and facilities. ACTengine® IMA203 cell therapy products are manufactured within 7 days, followed by a 7-day QC release testing at a success rate of >95% to reach the target dose. The company has also recently completed construction of a ~100,000 square foot R&D and GMP manufacturing facility with a modular design for efficient and cost-effective scalability intended to serve early-stage and Phase 2/3 clinical trials, as well as initial commercial supply. The new site will start GMP manufacturing of cell therapy products in early 2025. Meanwhile, the existing GMP facility, which is run in collaboration with UT Health, will remain active until YE 2025 and will also initially serve the Phase 2/3 registrational trial.

Following an RMAT designation in October 2023 and productive interactions with the FDA, Immatics plans to initiate a randomized Phase 2/3 trial in 4Q 2024 for IMA203 in patients with second-line or later (2L+) cutaneous melanoma, potentially also including uveal melanoma patients.

The Phase 2/3 trial is expected to assess IMA203 targeting PRAME in HLA-A*02:01-positive cutaneous melanoma patients versus a control arm. This approach is consistent with the FDA's "one-trial" approach 2 , i.e., a single randomized controlled trial to support accelerated approval and the verification of clinical benefit to achieve full approval. The high prevalence of PRAME (≥95%) in cutaneous melanoma may enable the company to enroll patients without PRAME pre-testing. This would enhance trial operations and would remove the need to develop a companion diagnostic for PRAME testing in this indication. The full trial design is currently being developed and is subject to further alignment with the FDA as part of the ongoing discussions. Further details of the final clinical trial design will be provided in 2H 2024.

IMA203 is being developed to treat patients with metastatic melanoma, a prevalent cancer type with increasing incidence both inside and outside the United States. Currently, eligible PRAME-positive melanoma patients for the ongoing trials, i.e., 2L+, HLA-A*02:01 positive, include ~3,000 cutaneous melanoma patients and ~300 eligible uveal melanoma patients 3 in the US.

ACTengine® IMA203CD8 (GEN2) monotherapy

As of the previously reported interim clinical update from November 8, 2023, the first data on the company's second-generation product candidate, IMA203CD8 (consisting of PRAME-specific functional CD8+ and CD4+ cells), demonstrated 56% (5/9) cORR with enhanced pharmacology compared to IMA203. mDOR was not reached (min 2.0+ months, max 11.5+ months) at a mFU of 4.8 months. As of the reported September 30, 2023, cut-off date, IMA203CD8 (GEN2) exhibited a manageable tolerability profile.

For IMA203CD8 (GEN2), Immatics cleared dose level 4a (DL4a, up to ~1.6x10 9 TCR-T cells) in December 2023. Immatics plans to continue dose escalation with the goal to define the optimal dose for further development. In addition to treating melanoma patients, Immatics has also started to expand its clinical footprint outside of melanoma to address a broader patient population with a particular focus on ovarian and uterine cancers.

A next data update for IMA203CD8 (GEN2) is planned for 2H 2024.

TCR Bispecifics Programs

Immatics' T cell engaging receptor (TCER®) candidates are next-generation, half-life extended TCR Bispecific molecules. They are designed to achieve a patient-convenient dosing schedule and to maximize efficacy while minimizing toxicities in patients through the proprietary format using a high-affinity TCR domain against the tumor target and a low-affinity T cell recruiter binding to the T cell.

Upcoming milestones for Immatics' clinical TCER® pipeline
Immatics seeks to deliver clinical proof-of-concept for its novel TCER® platform as quickly as possible and plans to provide first clinical data for IMA401 (MAGEA4/8) and IMA402 (PRAME) in 2H 2024.

Key objectives include:

  • Demonstrating tolerability of the novel, next-generation, half-life extended TCR Bispecifics format;
  • Optimizing dosing schedule to a less frequent regimen during dose escalation based on pharmacokinetics data;
  • Demonstrating initial clinical anti-tumor activity (i.e., confirmed objective responses according to RECIST 1.1).


The Phase 1 dose escalation basket trial to evaluate safety, tolerability and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors is ongoing. IMA401 targets an HLA-A*02:01-presented peptide that occurs identically in two different proteins, MAGEA4 and MAGEA8. This target peptide has been selected based on natural expression in native solid tumors at particularly high target density (peptide copy number per tumor cell identified by Immatics' proprietary quantitative mass spectrometry engine XPRESIDENT® is >5x higher than for a MAGEA4 peptide target used in other clinical trials).

MAGEA4 and MAGEA8 are expressed in multiple solid cancers, including lung cancer, head and neck cancer, melanoma, ovarian cancer, sarcoma and others. Tolerability continues to be manageable with transient low-grade CRS, lymphopenia and neutropenia at high doses, all of which are expected for a bispecific T cell engager. A premedication with low doses of dexamethasone administered prior to the first 4 infusions, as used with other approved bispecific products, has been implemented as a preventative measure for continued dose escalation. Since the implementation of this premedication, to date, no cases of high-grade neutropenia among the patients treated have been observed. Based on pharmacokinetics data, the treatment schedule for IMA401 was switched from weekly to bi-weekly dosing. Confirmed objective responses have been observed in multiple patients.

IMA401 is being developed in collaboration with Bristol Myers Squibb. First clinical data in at least 25 patients in dose escalation across all doses and multiple solid cancers is expected to be announced in 2H 2024.


Immatics initiated the Phase 1/2 trial investigating the company's fully owned TCER® candidate IMA402 in patients with recurrent and/or refractory solid tumors in August 2023 and the first patients have been dosed. Initial focus indications are ovarian cancer, lung cancer, uterine cancer and cutaneous and uveal melanoma, among others. IMA402 targets an HLA-A*02:01-presented peptide derived from the tumor antigen PRAME. This target peptide has been selected based on natural expression in native solid primary tumors and metastases at particularly high target density (peptide copy number per tumor cell identified by Immatics' proprietary quantitative mass spectrometry engine XPRESIDENT®).

Immatics has recently engaged Patheon UK Limited, a subsidiary of ThermoFisher Scientific Inc., for the manufacturing of clinical IMA402 batches for its use within a potential registration-enabling trial. Patient recruitment and dose escalation continue to scale. First clinical data in at least 15 patients in dose escalation across multiple solid cancers, but initially focused on melanoma, is anticipated to be announced in 2H 2024.

Corporate Development

  • On January 22, 2024, Immatics completed an offering of 18,313,750 ordinary shares at a public offering price of $11.00 per share. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, were approximately $201.5 million.

First Quarter 2024 Financial Results

Cash Position: Cash and cash equivalents, as well as other financial assets, total €564.0 million ($609.7 million 1 ) as of March 31, 2024, compared to €425.9 million ($460.4 million 1 ) as of December 31, 2023. The increase is mainly due to the public offering in January 2024, partly offset by ongoing research and development activities. The company projects a cash runway into 2027.

Revenue: Total revenue, consisting of revenue from collaboration agreements, was €30.3 million ($32.8 million 1 ) for the three months ended March 31, 2024, compared to €9.8 million ($10.6 million 1 ) for the three months ended March 31, 2023. The increase is mainly the result of the release of the deferred revenue following the termination of the Genmab collaboration.

Research and Development Expenses: R&D expenses were €32.1 million ($34.7 million 1 ) for the three months ended March 31, 2024, compared to €27.6 million ($29.8 million 1 ) for the three months ended March 31, 2023. The increase mainly resulted from costs associated with the advancement of the clinical pipeline candidates.

General and Administrative Expenses: G&A expenses were €11.6 million ($12.5 million 1 ) for the three months ended March 31, 2024, compared to €9.6 million ($10.4 million 1 ) for the three months ended March 31, 2023.

Net Profit and Loss: Net loss was €3.1 million ($3.4 million 1 ) for the three months ended March 31, 2024, compared to a net loss of €19.7 million ($21.3 million 1 ) for the three months ended March 31, 2023. The decrease of net loss resulted mainly from the one-time revenue related to the termination of the Genmab collaboration, as reported previously.

Full financial statements can be found in the 6-K filed with the Securities and Exchange Commission (SEC) on May 14, 2024, and published on the SEC website under .

Upcoming Investor Conferences

  • Bank of America Health Care Conference, Las Vegas (NV) – May 14 - 16, 2024
  • Jefferies Global Healthcare Conference, New York (NY) – June 5 - 7, 2024

To see the full list of events and presentations, visit .

- END -

About IMA203 and target PRAME
ACTengine ® IMA203 T cells are directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME), a protein frequently expressed in a large variety of solid cancers, thereby supporting the program's potential to address a broad cancer patient population. Immatics' PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics' proprietary mass spectrometry-based target discovery platform, XPRESIDENT ® . Through its proprietary TCR discovery and engineering platform XCEPTOR ® , Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine ® IMA203.

ACTengine ® IMA203 TCR-T is currently being evaluated in Phase 1 IMA203 monotherapy, and IMA203CD8 (GEN2) monotherapy, where IMA203 engineered T cells are co-transduced with a CD8αβ co-receptor. As previously reported, IMA203 in combination with an immune checkpoint inhibitor has been deprioritized.

About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

Immatics intends to use its website as a means of disclosing material non-public information. For regular updates you can also follow us on X , Instagram and LinkedIn .

Forward-Looking Statements
Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements concerning timing of data read-outs for product candidates, the timing, outcome and design of clinical trials, the nature of clinical trials (including whether such clinical trials will be registration-enabling), the timing of IND or CTA filing for pre-clinical stage product candidates, estimated market opportunities of product candidates, the Company's focus on partnerships to advance its strategy, and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may", "should", "expect", "plan", "target", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. All the scientific and clinical data presented within this press release are – by definition prior to completion of the clinical trial and a clinical study report – preliminary in nature and subject to further quality checks including customary source data verification.

For more information, please contact:

Trophic Communications
Phone: +49 171 3512733

Immatics N.V.
Jordan Silverstein
Head of Strategy
Phone: +1 346 319-3325

Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Loss of Immatics N.V.

Three months ended March 31,



(Euros in thousands, except
per share data)
Revenue from collaboration agreements 30,269 9,796
Research and development expenses (32,108) (27,581)
General and administrative expenses (11,642) (9,586)
Other income 12 941
Operating result (13,469) (26,430)
Change in fair value of liabilities for warrants 1,043 7,397
Other financial income 11,381 2,795
Other financial expenses (677) (3,509)
Financial result 11,747 6,683
Loss before taxes (1,722) (19,747)
Taxes on income (1,332)
Net loss (3,054) (19,747)
Net loss per share:
Basic (0.03) (0.26)
Diluted (0.04) (0.26)

Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.

Three months ended March 31,



(Euros in thousands)
Net loss (3,054) (19,747)
Other comprehensive income
Items that may be reclassified subsequently to profit or loss
Currency translation differences from foreign operations 336 564
Total comprehensive loss for the year (2,718) (19,183)

Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Financial Position of Immatics N.V.

As of

March  31,

December 31,

(Euros in thousands)
Current assets
Cash and cash equivalents 122,093 218,472
Other financial assets 441,857 207,423
Accounts receivables 1,781 4,093
Other current assets 22,666 19,382
Total current assets 588,397 449,370
Non-current assets
Property, plant and equipment 49,968 43,747
Intangible assets 1,501 1,523
Right-of-use assets 11,886 13,308
Other non-current assets 1,373 2,017
Total non-current assets 64,728 60,595
Total assets 653,125 509,965
Liabilities and shareholders' equity
Current liabilities
Provisions 1,740 -
Accounts payables 20,537 25,206
Deferred revenue 96,525 100,401
Liabilities for warrants 17,950 18,993
Lease liabilities 2,762 2,604
Other current liabilities 9,590 9,348
Total current liabilities 149,104 156,552
Non-current liabilities
Deferred revenue 91,358 115,527
Lease liabilities 11,877 12,798
Other non-current liabilities 4
Total non-current liabilities 103,235 128,329
Shareholders' equity
Share capital 1,031 847
Share premium 1,001,402 823,166
Accumulated deficit (600,347) (597,293)
Other reserves (1,300) (1,636)
Total shareholders' equity 400,768 225,084
Total liabilities and shareholders' equity 653,125 509,965

Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Cash Flows of Immatics N.V.

Three months ended March 31,



(Euros in thousands)
Cash flows from operating activities
Net profit/(loss) (3,054) (19,747)
Taxes on income 1,332
Profit/(loss) before tax (1,722) (19,747)
Adjustments for:
Interest income (6,294) (2,254)
Depreciation and amortization 3,014 1,811
Interest expenses 194 195
Equity-settled share-based payment 4,297 6,103
Net foreign exchange differences and expected credit losses (4,553) 3,143
Change in fair value of liabilities for warrants (1,043) (7,397)
Changes in:
Decrease/(increase) in accounts receivables 2,312 880
Decrease/(increase) in other assets 574 234
(Decrease)/increase in deferred revenue, accounts payables and other liabilities (31,674) (7,793)
Interest received 2,484 1,189
Interest paid (194) (79)
Income tax paid
Net cash (used in)/provided by operating activities (32,605) (23,715)
Cash flows from investing activities
Payments for property, plant and equipment (9,174) (4,317)
Payments for intangible assets (2) (8)
Proceeds from disposal of property, plant and equipment
Payments for investments classified in Other financial assets (290,599) (67,735)
Proceeds from maturity of investments classified in Other financial assets 57,957 68,341
Net cash (used i n)/provided by investing activities (241,818) (3,719)
Cash flows from financing activities
Proceeds from issuance of shares to equity holders 185,669
Transaction costs deducted from equity (11,548)
Payments related to lease liabilities 524 (866)
Net cash provided by/(used in) financing activities 174,645 (866)
Net (decrease)/increase in cash and cash equivalents (99,778) (28,300)
Cash and cash equivalents at beginning of the year 218,472 148,519
Effects of exchange rate changes and expected credit losses on cash and cash equivalents 3,399 (2,300)
Cash and cash equivalents at end of the year 122,093 117,919

Immatics N.V. and subsidiaries
Condensed Consolidated Statement of Changes in Shareholders' equity of Immatics N.V.

(Euros in thousands)






Balance as of January 1, 2023 767 714,177 (500,299 ) (1,481) 213,164
Other comprehensive income 564 564
Net loss (19,747) (19,747)
Comprehensive loss for the year (19,747) 564 (19,183)
Equity-settled share-based compensation 6,103 6,103
Share options exercised
Issue of share capital – net of transaction costs
Balance as of March 31, 2023 767 720,280 (520,046) (917) 200,084
Balance as of January 1, 2024 847 823,166 (597,293 ) (1,636) 225,084
Other comprehensive income 336 336
Net loss (3,054) (3,054)
Comprehensive loss for the year (3,054) 336 (2,718)
Equity-settled share-based compensation 4,297 4,297
Share options exercised 1 682 683
Issue of share capital – net of transaction costs 183 173,257 173,440
Balance as of March 31, 2024 1,031 1,001,402 (600,347) (1,300) 400,786

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences:

2024 RBC Capital Markets Global Healthcare Conference
Tuesday, May 14, 2024 at 10:00 a.m. ET in New York, NY

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Logistics management concept.

The Business Case for Vertical Integration

Business models and go-to-market strategies are important elements of any investment decision.

In that regard, a vertically integrated business model offers several unique advantages over traditional business models, including enhanced resilience and access to multiple revenue streams across the value chain.

Understanding vertically integrated business models can help investors evaluate investment opportunities, particularly in new and emerging market segments.

Keep reading...Show less
Pills spilling out of a pill bottle on a yellow background.

Pharma Stocks: 5 Biggest Companies in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less
Mushroom displayed on podium.

Functional Mushrooms: A Growing Opportunity

Berries aren't the only superfood making waves in recent years. Mushrooms have been gaining a great deal of popularity amongst consumers, particularly as knowledge about their benefits continues to spread.

A special class of fungi, known as functional mushrooms, are of particular interest to mushroom enthusiasts, driving a movement toward functional living and greater health

And companies are increasingly tapping into this interest, as well as the commercial opportunities that go along with it. Investors looking to gain a foothold in the health and wellness industry can greatly benefit from a deeper understanding of functional mushrooms — what they are, their benefits and why they continue to gain traction.

Keep reading...Show less
Fungtional Labs

Fungtional Labs

Keep reading...Show less
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024

Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II study evaluating CardiolRx™ in patients with acute myocarditis

ARCHER trial rationale and design also accepted for publication in the journal ESC Heart Failure

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News